Aridis Pharmaceuticals Inc.

1.23-0.0200-1.60%Vol 43.01K1Y Perf -82.76%
Jun 27th, 2022 15:59 DELAYED
BID1.20 ASK1.61
Open1.30 Previous Close1.25
Pre-Market- After-Market1.37
 - -  0.14 11.38%
Target Price
9.67 
Analyst Rating
Strong Buy 1.00
Potential %
686.18 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
5.12 
Earnings Rating
Neutral
Market Cap21.77M 
Earnings Date
11th Aug 2022
Alpha-0.04 Standard Deviation0.19
Beta0.42 

Today's Price Range

1.211.37

52W Range

0.88007.72

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-11.35%
1 Month
27.55%
3 Months
-24.24%
6 Months
-52.65%
1 Year
-82.76%
3 Years
-88.74%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ARDS1.23-0.0200-1.60
AAPL141.660.00000.00
GOOG2 332.45-38.3100-1.62
MSFT264.89-2.8100-1.05
XOM89.032.13002.45
WFC40.24-0.5200-1.28
JNJ182.12-0.1700-0.09
FB196.640.99000.51
GE66.71-0.2900-0.43
JPM116.38-0.9400-0.80
ProfitabilityValueIndustryS&P 500US Markets
-
-3 535.10
-3 503.00
-2 324.00
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-63.67
-2.54
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.51-0.4413.73
Q04 2021-0.58-0.92-58.62
Q03 2021-0.54-1.94-259.26
Q02 2021-0.57-0.553.51
Q01 2021-0.60-0.77-28.33
Q04 2020-0.54-0.59-9.26
Q03 2020-0.55-0.65-18.18
Q02 2020-0.72-0.4734.72
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.0640.00Positive
9/2022 QR-0.08--
12/2022 FY-0.34--
12/2023 FY-0.60--
Next Report Date11th Aug 2022
Estimated EPS Next Report-0.06
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume43.01K
Shares Outstanding17.70K
Shares Float16.26M
Trades Count219
Dollar Volume54.93K
Avg. Volume58.23K
Avg. Weekly Volume44.30K
Avg. Monthly Volume68.08K
Avg. Quarterly Volume62.32K

Aridis Pharmaceuticals Inc. (NASDAQ: ARDS) stock closed at 1.25 per share at the end of the most recent trading day (a -8.09% change compared to the prior day closing price) with a volume of 56.55K shares and market capitalization of 21.77M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 32 people. Aridis Pharmaceuticals Inc. CEO is Vu Truong.

The one-year performance of Aridis Pharmaceuticals Inc. stock is -82.76%, while year-to-date (YTD) performance is -46.35%. ARDS stock has a five-year performance of %. Its 52-week range is between 0.88 and 7.72, which gives ARDS stock a 52-week price range ratio of 5.12%

Aridis Pharmaceuticals Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 15.71, a price-to-sale (PS) ratio of 13.09, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -223.31%, a ROC of -770.63% and a ROE of 319.08%. The company’s profit margin is -%, its EBITDA margin is -3 503.00%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Aridis Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.06 for the next earnings report. Aridis Pharmaceuticals Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Aridis Pharmaceuticals Inc. is Strong Buy (1), with a target price of $9.67, which is +686.18% compared to the current price. The earnings rating for Aridis Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aridis Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aridis Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.02, ATR14 : 0.14, CCI20 : 19.85, Chaikin Money Flow : 0.16, MACD : 0.06, Money Flow Index : 70.31, ROC : 17.92, RSI : 49.05, STOCH (14,3) : 31.51, STOCH RSI : 0.00, UO : 37.93, Williams %R : -68.49), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aridis Pharmaceuticals Inc. in the last 12-months were: Eric Patzer (Buy at a value of $25 047), Hasan Jafri (Buy at a value of $21 147), John F. Hamilton (Buy at a value of $9 740), Vu Truong (Buy at a value of $25 550)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aridis Pharmaceuticals Inc.

Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.

CEO: Vu Truong

Telephone: +1 408 385-1742

Address: 5941 Optical Court, San Jose 95138, CA, US

Number of employees: 32

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

61%39%

Bearish Bullish

64%36%

Bearish Bullish

57%43%

TipRanks News for ARDS

Thu, 17 Feb 2022 15:56 GMT Aridis Pharmaceuticals (ARDS) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits